Balance Therapeutics

Balance Therapeutics

Facts & Stats

  • Developmental intellectual disabilities including Down Syndrome, are characterized by an IQ <70 and by deficits in academic, adaptive and interpersonal skills.There are about 250,000 people with Down syndrome in the US.
  • Balance Therapeutics’ Phase 1b/2a clinical trial DS102 for cognitive impairment in Down syndrome is currently being conducted in Australia and will enroll 90 people with Down syndrome age 13 to 35. 
  • BTD-001 has had decades of safe human experience and has served as rescue therapy for barbiturate overdosing, was a component in respiratory medications, and was used to treat senile dementia.

Adamas

Adamas

Facts & Stats

  • Aminoadamantanes were first synthesized in the 1950s and include FDA-approved amantadine, rimantadine and memantine.
  • Over 6 million people in the U.S. suffer from chronic neurodegenerative diseases such as dementia and Parkinson’s disease.
  • Adamas is developing Advantaged Therapeutics for dementia and Parkinson’s disease that are designed to provide improved efficacy and tolerability and to simplify daily drug regimens.

 

Syndicate content